In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PolyTherics Ltd.

Division of Abzena Ltd./PolyTherics Ltd.

Latest From PolyTherics Ltd.

Device/Diagnostics Quarterly Deal Statistics, Q3 2014

Device financing decreased to $734 million in Q3, less than half the Q2 total, and the $4.9 billion in M&As was a sharp decline versus Q2. Diagnostics fundraising, at $399 million, showed a 31% drop from Q2, and Merck KGAA’s $16.7 billion buy of Sigma-Aldrich made up 96% of the Q3 M&A activity.

Medical Device Deals

Start-Up Quarterly Statistics, Q3 2014

Start-ups raised $1.19 billion in Q3 2014, 33% more than last quarter. Several reverse licensing alliances were penned; five acquisitions were signed, four in biopharma and one in the device sector.

BioPharmaceutical Medical Device

Abzena Is New Identity For PolyTherics-Antitope; Includes Cambridge HQ

Following last year’s merger of PolyTherics and Antitope, the provider of services to improve biopharmaceutical products has settled on Cambridge in the U.K. for its HQ, while a new holding structure hints at more M&A to come.

BioPharmaceutical United Kingdom

European Notebook: CHMP Opens Up A Bit; France Looks For $1B In Price Cuts; Spain Making Good On Pharma Debts

Europe's top scientific advisory panel, the CHMP, could reveal more of its thoughts on product approvals next year. French biopharma tries to stave off deep cuts in budgetary debate; Germany may consider more health reforms following recent elections; Invesco, Servier see exec changes

BioPharmaceutical Europe
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
      • Site Specific
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Abzena Ltd.
  • Senior Management
  • John Burt, PhD, CEO
    Georg Buchner, PhD, VP, Bus. Dev.
    Tim Brown, Fin. Mgr.
    Antony Godwin, PhD, Dir., Science & Tech.
  • Contact Info
  • PolyTherics Ltd.
    Phone: (44) 20 7691 4927
    London BioScience Innovation Centre
    2 Royal College
    London, NW1 0NH